Ivhebex (Human Hepatitis B Immunoglobulin)

Ivhebex, a hepatitis B immune globulin, is used in the prevention of HBV infection through passive immunization.

• Post‑exposure prophylaxis: Provides immediate protection against hepatitis B virus after accidental or occupational exposure.
• Newborn prophylaxis: Administered to infants born to hepatitis B surface antigen‑positive mothers to prevent perinatal transmission.
• Pre‑transplant prophylaxis: Used in patients undergoing liver transplantation to reduce the risk of hepatitis B recurrence.
• Immunocompromised patient prophylaxis: Provides passive immunity for individuals with weakened immune systems who are at high risk of HBV infection.

• Human Hepatitis B Immunoglobulin in Ivhebex consists of purified anti‑HBs antibodies derived from pooled human plasma. After intravenous administration, the antibodies bind to hepatitis B surface antigen, neutralizing circulating virus and preventing its entry into hepatocytes. This passive transfer of immunity supplies immediate, short‑term protection until the recipient’s own active immune response can develop. The effect typically lasts for several weeks, providing a bridge to vaccine‑induced active immunity.

Ivhebex may be associated with infusion‑related reactions and immunologic events.

Common Side Effects

• Fever: Mild to moderate temperature elevation occurring shortly after infusion.
• Headache: Transient headache reported during or after administration.
• Nausea: Occasional nausea without vomiting.
• Injection site discomfort: Localized pain or erythema at the infusion site.

Serious or Rare Side Effects

• Anaphylaxis: Severe allergic reaction requiring immediate medical intervention.
• Acute hemolysis: Rapid destruction of red blood cells leading to anemia.
• Thromboembolic events: Blood clot formation in veins or arteries.
• Serum sickness‑like reaction: Fever, rash, arthralgia occurring days after infusion.

Before using Ivhebex, consider the following precautions to ensure safe administration.

• Assess patient history: Verify prior exposure to blood products and any known hypersensitivity to immunoglobulins.
• Monitor during infusion: Observe vital signs and watch for signs of anaphylaxis or infusion reactions.
• Adjust for renal impairment: Use caution in patients with severe kidney dysfunction.
• Avoid concurrent immunoglobulin therapy: Do not administer other immunoglobulin products simultaneously without clinical justification.
• Pregnancy and lactation: Use only if the potential benefit outweighs the risk, as safety data are limited.
• Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake the product.

Ivhebex can interact with certain medications and vaccines; awareness of these interactions helps prevent reduced efficacy or increased adverse effects.

Major Interactions (Avoid)

• Live vaccines: Co‑administration may diminish vaccine effectiveness; avoid simultaneous use.
• Immunosuppressants: May increase risk of infection; monitor patient closely.

Moderate Interactions (Monitor Closely)

• Anticoagulants: Immunoglobulin may affect coagulation parameters; check INR or aPTT.
• High‑dose steroids: May alter immunoglobulin metabolism; adjust dosing if needed.
• Other blood products: Concurrent transfusions can affect antibody levels; stagger administration.